CA2339913C - Pharmaceutical formulations and method for making - Google Patents
Pharmaceutical formulations and method for making Download PDFInfo
- Publication number
- CA2339913C CA2339913C CA002339913A CA2339913A CA2339913C CA 2339913 C CA2339913 C CA 2339913C CA 002339913 A CA002339913 A CA 002339913A CA 2339913 A CA2339913 A CA 2339913A CA 2339913 C CA2339913 C CA 2339913C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical formulation
- oral pharmaceutical
- agent
- formulation
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 title description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 94
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 238000009472 formulation Methods 0.000 claims abstract description 70
- 239000008187 granular material Substances 0.000 claims abstract description 46
- -1 sucrose ester Chemical class 0.000 claims abstract description 43
- 229930006000 Sucrose Natural products 0.000 claims abstract description 41
- 239000005720 sucrose Substances 0.000 claims abstract description 41
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 28
- 239000000194 fatty acid Substances 0.000 claims abstract description 28
- 229930195729 fatty acid Natural products 0.000 claims abstract description 28
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 27
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 25
- 238000002844 melting Methods 0.000 claims abstract description 20
- 230000008018 melting Effects 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 239000008188 pellet Substances 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims abstract description 9
- 238000005453 pelletization Methods 0.000 claims abstract description 9
- 239000000155 melt Substances 0.000 claims abstract description 8
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims description 38
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 claims description 38
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims description 28
- 229960003312 retigabine Drugs 0.000 claims description 28
- 239000003826 tablet Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 15
- 229960000623 carbamazepine Drugs 0.000 claims description 15
- 229940095670 calcium valproate Drugs 0.000 claims description 14
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 12
- 229960001597 nifedipine Drugs 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000001069 triethyl citrate Substances 0.000 claims description 7
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000013769 triethyl citrate Nutrition 0.000 claims description 7
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 claims description 7
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- PIZHURYFCSGTJX-UHFFFAOYSA-L calcium;2-propylpentanoate Chemical compound [Ca+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC PIZHURYFCSGTJX-UHFFFAOYSA-L 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 6
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 6
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 claims description 5
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 5
- 229960004380 tramadol Drugs 0.000 claims description 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 229960004166 diltiazem Drugs 0.000 claims description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 4
- 229960003667 flupirtine Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 claims description 3
- DSFGXPJYDCSWTA-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C DSFGXPJYDCSWTA-UHFFFAOYSA-N 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 claims description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 3
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 3
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims description 3
- WKACQPMBGWZDMR-UHFFFAOYSA-N Vincamin Natural products CC=C1/CN2CCC34CC2C1C(=C3Nc5ccccc45)C=O WKACQPMBGWZDMR-UHFFFAOYSA-N 0.000 claims description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 3
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000911 benserazide Drugs 0.000 claims description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 3
- 229960000516 bezafibrate Drugs 0.000 claims description 3
- 229960001415 buflomedil Drugs 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 3
- 229960001259 diclofenac Drugs 0.000 claims description 3
- 229960004704 dihydroergotamine Drugs 0.000 claims description 3
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 3
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004993 dimenhydrinate Drugs 0.000 claims description 3
- 229960001066 disopyramide Drugs 0.000 claims description 3
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 claims description 3
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001389 doxazosin Drugs 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002297 fenofibrate Drugs 0.000 claims description 3
- 229960002490 fosinopril Drugs 0.000 claims description 3
- 229960003883 furosemide Drugs 0.000 claims description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004580 glibenclamide Drugs 0.000 claims description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 3
- 229960004502 levodopa Drugs 0.000 claims description 3
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 3
- 229960004027 molsidomine Drugs 0.000 claims description 3
- 229960005181 morphine Drugs 0.000 claims description 3
- 229960001132 naftidrofuryl Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 239000002664 nootropic agent Substances 0.000 claims description 3
- 229960001476 pentoxifylline Drugs 0.000 claims description 3
- 229960004526 piracetam Drugs 0.000 claims description 3
- 229960001085 piretanide Drugs 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 3
- 229960003908 pseudoephedrine Drugs 0.000 claims description 3
- 229960001404 quinidine Drugs 0.000 claims description 3
- 229960002052 salbutamol Drugs 0.000 claims description 3
- 239000007940 sugar coated tablet Substances 0.000 claims description 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003708 sumatriptan Drugs 0.000 claims description 3
- MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003658 talinolol Drugs 0.000 claims description 3
- 229960000278 theophylline Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 3
- 229960000604 valproic acid Drugs 0.000 claims description 3
- 229960001722 verapamil Drugs 0.000 claims description 3
- 229940118318 xanthinol Drugs 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 229940125682 antidementia agent Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940125683 antiemetic agent Drugs 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940124572 antihypotensive agent Drugs 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 229940125688 antiparkinson agent Drugs 0.000 claims description 2
- 239000000939 antiparkinson agent Substances 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 208000018300 basal ganglia disease Diseases 0.000 claims description 2
- 239000002371 cardiac agent Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 239000005555 hypertensive agent Substances 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- OWMFSWZUAWKDRR-UHFFFAOYSA-N Norfenefrine hydrochloride Chemical compound [Cl-].[NH3+]CC(O)C1=CC=CC(O)=C1 OWMFSWZUAWKDRR-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- 235000021355 Stearic acid Nutrition 0.000 claims 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- 229960004574 azelastine Drugs 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229960005069 calcium Drugs 0.000 claims 2
- 150000004683 dihydrates Chemical class 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 claims 2
- 229960000201 isosorbide dinitrate Drugs 0.000 claims 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims 2
- 229960003827 isosorbide mononitrate Drugs 0.000 claims 2
- 229940071257 lithium acetate Drugs 0.000 claims 2
- 229940008015 lithium carbonate Drugs 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 229960001856 norfenefrine Drugs 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229960002371 pentifylline Drugs 0.000 claims 2
- 239000008117 stearic acid Substances 0.000 claims 2
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 2
- 229960005105 terbutaline sulfate Drugs 0.000 claims 2
- 229960002784 thioridazine Drugs 0.000 claims 2
- 229960001402 tilidine Drugs 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004688 venlafaxine Drugs 0.000 claims 2
- 229960002726 vincamine Drugs 0.000 claims 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000002460 anti-migrenic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 230000001813 broncholytic effect Effects 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 51
- 239000000126 substance Substances 0.000 description 33
- 238000011156 evaluation Methods 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 238000007909 melt granulation Methods 0.000 description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000005469 granulation Methods 0.000 description 12
- 230000003179 granulation Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000011230 binding agent Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 101100235626 Caenorhabditis elegans hlb-1 gene Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 229940060367 inert ingredients Drugs 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000007757 hot melt coating Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006082 mold release agent Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 3
- 229940116224 behenate Drugs 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 235000019700 dicalcium phosphate Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 150000003445 sucroses Chemical class 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008385 outer phase Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000449 pharmaceutical disintegrant Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000003340 retarding agent Substances 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004815 meprobamate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000013354 porous framework Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000011417 postcuring Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960003107 tramadol hydrochloride Drugs 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 125000000969 xylosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
Abstract
The invention relates to an oral pharmaceutical formulation with variably adjustable release rate, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient wherein when the dosage form is a granule or a pellet, the formulation is made by melting the oral formulation, and granulating or pelletizing the melt.
Description
PHARMACEUTICAL FORMULATIONS AND METHOD FOR MAKING
Field of the invention The present invention relates to new oral pharmaceutical formulations with variably adjustable release characteristics for the active ingredient, suitably in the form of granulates, pellets, tablets, film coated tablets, microtablets, sugar coated tablets, capsules or therapeutic systems, as well as to methods for their manufacture by melt granulation or melt pelletization.
Back rg ound A reduced frequency of taking medicinal drugs and, in the ideal case, taking such drugs only once daily can play an important role in their use.
One tablet in the mornings or the evenings is usually taken more regularly than are several tablets spread over the day. In addition to the convenience, this improved patient compliance also has a positive effect on the healing process. In addition, the better compatibility of the active ingredient, which is frequently associated with a reduced frequency of taking it, benefits the patient. The latter is related to the need to maintain the effective plasma concentration for a longer time and to the mostly more uniform plasma levels, at which incompatible peak levels are largely avoided.
In exceptional cases, a single administration can already be realized by the kinetic or dynamic properties of an active ingredient, such as by a long elimination half-life. In most cases, however, effective plasma levels over 12 to 24 hours become possible only by pharmaceutical and technological measures, such as the delayed release of the active ingredient from the form in which it is administered.
The literature describes a series of solutions which in principle, depending on the chemical and physical properties of the active ingredient, have advantages or disadvantages (e.g. see the review article: Recent Trends and Progress in Sustained or Controlled Oral Delivery of Some Water Soluble Drugs, Drug Development and Industrial Pharmacy 21 (9), 1037 - 1070 (1998)).
The state of the art is given, for example, also in one of the newer textbooks of pharmaceutical technology (Voigt, R., Pharmazeutische Technologie (Pharmaceutical Technology), Ullstein Mosby Publishers 1993, page 293 ff).
According to this, the action of drugs can be prolonged by measures such as: varying the molecule, for example, by forming a salt or an ester, changing the active ingredient modification, the particle size, the choice of appropriate inert ingredients and the appropriate methods.
Some exemplary possibilities are discussed below.
(a) Matrix forms for controlled release of drugs These are characterized by an insoluble, possibly porous framework of indigestible fats, waxes, polymers or also inorganic matrix-forming materials.
The active ingredient is incorporated into this framework and released by diffusion, erosion or matrix decomposition.
(b) Hydrocolloid forms for controlled release of drugs The drug is incorporated in this case hydrocolloid matrices, such as cellulose derivatives. After the drug is ingested, a gel is formed by the digestion fluids.
The active ingredient diffuses from the gel at a rate, which depends on the surface area and the gel viscosity.
Field of the invention The present invention relates to new oral pharmaceutical formulations with variably adjustable release characteristics for the active ingredient, suitably in the form of granulates, pellets, tablets, film coated tablets, microtablets, sugar coated tablets, capsules or therapeutic systems, as well as to methods for their manufacture by melt granulation or melt pelletization.
Back rg ound A reduced frequency of taking medicinal drugs and, in the ideal case, taking such drugs only once daily can play an important role in their use.
One tablet in the mornings or the evenings is usually taken more regularly than are several tablets spread over the day. In addition to the convenience, this improved patient compliance also has a positive effect on the healing process. In addition, the better compatibility of the active ingredient, which is frequently associated with a reduced frequency of taking it, benefits the patient. The latter is related to the need to maintain the effective plasma concentration for a longer time and to the mostly more uniform plasma levels, at which incompatible peak levels are largely avoided.
In exceptional cases, a single administration can already be realized by the kinetic or dynamic properties of an active ingredient, such as by a long elimination half-life. In most cases, however, effective plasma levels over 12 to 24 hours become possible only by pharmaceutical and technological measures, such as the delayed release of the active ingredient from the form in which it is administered.
The literature describes a series of solutions which in principle, depending on the chemical and physical properties of the active ingredient, have advantages or disadvantages (e.g. see the review article: Recent Trends and Progress in Sustained or Controlled Oral Delivery of Some Water Soluble Drugs, Drug Development and Industrial Pharmacy 21 (9), 1037 - 1070 (1998)).
The state of the art is given, for example, also in one of the newer textbooks of pharmaceutical technology (Voigt, R., Pharmazeutische Technologie (Pharmaceutical Technology), Ullstein Mosby Publishers 1993, page 293 ff).
According to this, the action of drugs can be prolonged by measures such as: varying the molecule, for example, by forming a salt or an ester, changing the active ingredient modification, the particle size, the choice of appropriate inert ingredients and the appropriate methods.
Some exemplary possibilities are discussed below.
(a) Matrix forms for controlled release of drugs These are characterized by an insoluble, possibly porous framework of indigestible fats, waxes, polymers or also inorganic matrix-forming materials.
The active ingredient is incorporated into this framework and released by diffusion, erosion or matrix decomposition.
(b) Hydrocolloid forms for controlled release of drugs The drug is incorporated in this case hydrocolloid matrices, such as cellulose derivatives. After the drug is ingested, a gel is formed by the digestion fluids.
The active ingredient diffuses from the gel at a rate, which depends on the surface area and the gel viscosity.
(c) Coated (membrane-controlled) forms for controlled release of drugs Active ingredient particles or drug forms are enveloped in these cases by a barrier. Diffusion through the diffusion barrier determines the rate of release of the active ingredient. Plasticizers or pore-forming agents can be added to increase the diffusion rate.
(d) Effect of the specific surface area For active ingredients having a low water solubility, there is generally a clear relationship between their rate of dissolution and their specific surface area. A
defined particle size distribution and, and thus a particular specific surface area can be achieved by selective crystallization of the active ingredient, by screening or by grinding.
The larger the particles, the smaller is the specific surface area and the slower is the release of active ingredient.
(e) Mixed forms of diffusion, erosion and dissolving processes Drug forms are known, for which the delayed release of the active ingredient is based on a combination of diffusion, erosion and dissolving processes.
Melt granulation represents a particularly interesting and, with respect to the release of active ingredient, very variably usable method. Melt granulation or thermoplastic granulation is a process, for which granulate bonding is brought about through the use of a low-melting component, as well as under the influence of thermal energy (Ludemann, J.: APV Course 231 of June 17 to 18, 1996).
A differentiation is made here between two sub-types. In the case of wet granulation, the process temperature is above the melting point of the binding component.
(d) Effect of the specific surface area For active ingredients having a low water solubility, there is generally a clear relationship between their rate of dissolution and their specific surface area. A
defined particle size distribution and, and thus a particular specific surface area can be achieved by selective crystallization of the active ingredient, by screening or by grinding.
The larger the particles, the smaller is the specific surface area and the slower is the release of active ingredient.
(e) Mixed forms of diffusion, erosion and dissolving processes Drug forms are known, for which the delayed release of the active ingredient is based on a combination of diffusion, erosion and dissolving processes.
Melt granulation represents a particularly interesting and, with respect to the release of active ingredient, very variably usable method. Melt granulation or thermoplastic granulation is a process, for which granulate bonding is brought about through the use of a low-melting component, as well as under the influence of thermal energy (Ludemann, J.: APV Course 231 of June 17 to 18, 1996).
A differentiation is made here between two sub-types. In the case of wet granulation, the process temperature is above the melting point of the binding component.
The latter is present during the granulation as a liquid or semi-solid component. In melt granulation, drying is replaced by cooling.
Melt granulation is a sinter granulation, when the process temperature does not reach the melting point of the binding component. Only local melting at the surface of the particles takes place, so that the surfaces diffuse into one another (Voigt, R: Lehrbuch of pharmezeutischen Technologie (Textbook of Pharmaceutical Technology), Verlag Chemie, page 159 (1984)).
The low-melting component can be an active component or an inactive ingredient. For stability reasons, the melting points of the substances are generally above 35 C. The most frequently used materials have melting points ranging from 50 to 90 C.
Known active ingredients, as fusible substances, are phenyl salicylate, ibuprofen, a-liponic acid and meprobamate. Water soluble, swellable and lipophilic substances are used as fusible inert ingredients. For example, Macrogol, Polyvidon and polymethacrylic acid derivatives are used as hydrophilic materials. Hydrocarbons (paraffins), waxes, fats and fatty acids are examples of inert lipophilic materials. (Flanders, P.; Dyer, G.A.; Jordan, D.;
Drug Dev. Ind. Pharm. 13 (&), 1001 - 1022 (1987); Schaefer, T.; Holm, P.;
Kristensen, H.G.; Drug Dev. Ind. Pharm. 16, 1249 - 1277 (1990); McTaggart, C.M. et al.;
Int. J.
Pharm. 19, 139 - 148 (1984); Kinget, R.; Kemel, R.; Acta Pharm. Technol 31, 57 (1985)).
Melt granulation is usually carried out in fluidized bed granulators, centrifugal fluidized bed equipment or high-speed intensive mixers. The use especially of the latter has processing advantages, since a cost intensive air preparation can be omitted.
Compared to conventional granulation methods with organic solvents. There are no expenses for explosion protection and solvent recovery compared to nonaqueous granulation. There are also no residual solvents in the product. There are no energy-consuming drying processes. The use of so-called one-reactor systems is preferred in such cases.
The process of melt granulation can in general be shown as follows:
Mixing Mixing Addition of binder (solid Heating aggregate state) 1 Heating Addition of binder (solid aggregate state) Granulation Granulation I I
Cooling Cooling optionally classifying optionally classifying Fusible binders can be added in the solid or liquid state, that is, in the molten state.
For solid addition, the fusible material is melted during the process. For this reason, this method is also referred to as the melting method.
For the latter method, either the solid components are transferred to the reactor first and the liquid binder is added or, corresponding to the so-called fusion method, the liquid binder is added to the reactor and the solid materials are stirred in. For this purpose, heating is carried out before the addition of the binder.
Melt granulation is a sinter granulation, when the process temperature does not reach the melting point of the binding component. Only local melting at the surface of the particles takes place, so that the surfaces diffuse into one another (Voigt, R: Lehrbuch of pharmezeutischen Technologie (Textbook of Pharmaceutical Technology), Verlag Chemie, page 159 (1984)).
The low-melting component can be an active component or an inactive ingredient. For stability reasons, the melting points of the substances are generally above 35 C. The most frequently used materials have melting points ranging from 50 to 90 C.
Known active ingredients, as fusible substances, are phenyl salicylate, ibuprofen, a-liponic acid and meprobamate. Water soluble, swellable and lipophilic substances are used as fusible inert ingredients. For example, Macrogol, Polyvidon and polymethacrylic acid derivatives are used as hydrophilic materials. Hydrocarbons (paraffins), waxes, fats and fatty acids are examples of inert lipophilic materials. (Flanders, P.; Dyer, G.A.; Jordan, D.;
Drug Dev. Ind. Pharm. 13 (&), 1001 - 1022 (1987); Schaefer, T.; Holm, P.;
Kristensen, H.G.; Drug Dev. Ind. Pharm. 16, 1249 - 1277 (1990); McTaggart, C.M. et al.;
Int. J.
Pharm. 19, 139 - 148 (1984); Kinget, R.; Kemel, R.; Acta Pharm. Technol 31, 57 (1985)).
Melt granulation is usually carried out in fluidized bed granulators, centrifugal fluidized bed equipment or high-speed intensive mixers. The use especially of the latter has processing advantages, since a cost intensive air preparation can be omitted.
Compared to conventional granulation methods with organic solvents. There are no expenses for explosion protection and solvent recovery compared to nonaqueous granulation. There are also no residual solvents in the product. There are no energy-consuming drying processes. The use of so-called one-reactor systems is preferred in such cases.
The process of melt granulation can in general be shown as follows:
Mixing Mixing Addition of binder (solid Heating aggregate state) 1 Heating Addition of binder (solid aggregate state) Granulation Granulation I I
Cooling Cooling optionally classifying optionally classifying Fusible binders can be added in the solid or liquid state, that is, in the molten state.
For solid addition, the fusible material is melted during the process. For this reason, this method is also referred to as the melting method.
For the latter method, either the solid components are transferred to the reactor first and the liquid binder is added or, corresponding to the so-called fusion method, the liquid binder is added to the reactor and the solid materials are stirred in. For this purpose, heating is carried out before the addition of the binder.
In the case of intensive mixers, energy can be supplied in various ways:
mechanical energy by mixing tools and choppers;
contact heat by way of a heating jacket;
radiation energy by IR or microwave;
hot air introduction into the product bed.
A large number of methods for producing such formulations are also known from the patent literature. Formulations with a controlled release, which can be produced by way of melt granulation, are described, for example, in German patent No.
2,426,812, European patents 351,580; 654,263; 672,416; and 729,751 and in WO
93/18753. The last one describes a process, in which water-insoluble, hydrophobic, wax-like substances are added at a later time in the production process to the prepared pellets at a temperature, at which these substances melt and lead to a coating of these substances.
This process is referred to as "hot-melt coating".
On the assumption that all of the starting materials, participating in the process are thermally stable under the existing process conditions, melt granulation is an interesting alternative to other granulation methods, such as granulating, for example, with organic solvents or granulating with water.
Melt pelletizing represents a special form of carrying out the process, for which the granulate particles are produced with a largely uniform size and rounded shape.
In spite of the large number of known non-active excipients, which can be melted, only a few such materials with graded HLB values (hydrophilic-lipophilic balance values) are described, which are particularly suitable for melt granulation processes or melt pelletization processes.
Representatives of the few inert ingredients with graded HLB values are hydrogenated edible fats, which are available under the trade name of Gelucires, or the sorbitol esters of fatty acids, which are known for example, as Span. However, these also do not cover the broad HLB range from I to 16.
With the classical, fusible inert ingredients, the release rates can be varied only by the retarding agent selected or by the amount of this agent.
Frequently, a binder can be processed only in combination with a different fusible binder, such as polyethylene glycol, since its granulate-forming alone is inadequate. These binders also require the addition of lubricants or mold release agents. Some have a wax-like consistency. In the case of the known methods of melt granulation, the resulting, solidified granulates must frequently be subjected to an expensive screening process to comminute the product.
When preparing controlled release compositions by a coating procedure, destruction of the film coating is frequently observed during pressing because of the partially brittle, but also relatively thin film coatings, unless such a destruction is counteracted with a relatively large amount of external phase. When the film coating is destroyed, the release rate of active ingredient from the tablets is increased. This means that the release of active ingredient from these tablets mostly depends on the pressing force. Frequently, in the case of this method, the release of active ingredient is adjusted by the amount sprayed on during the manufacturing process. Depending on the film formation and the porosity, the release rate of active ingredient may change during storage, for example, due to post-curing.
mechanical energy by mixing tools and choppers;
contact heat by way of a heating jacket;
radiation energy by IR or microwave;
hot air introduction into the product bed.
A large number of methods for producing such formulations are also known from the patent literature. Formulations with a controlled release, which can be produced by way of melt granulation, are described, for example, in German patent No.
2,426,812, European patents 351,580; 654,263; 672,416; and 729,751 and in WO
93/18753. The last one describes a process, in which water-insoluble, hydrophobic, wax-like substances are added at a later time in the production process to the prepared pellets at a temperature, at which these substances melt and lead to a coating of these substances.
This process is referred to as "hot-melt coating".
On the assumption that all of the starting materials, participating in the process are thermally stable under the existing process conditions, melt granulation is an interesting alternative to other granulation methods, such as granulating, for example, with organic solvents or granulating with water.
Melt pelletizing represents a special form of carrying out the process, for which the granulate particles are produced with a largely uniform size and rounded shape.
In spite of the large number of known non-active excipients, which can be melted, only a few such materials with graded HLB values (hydrophilic-lipophilic balance values) are described, which are particularly suitable for melt granulation processes or melt pelletization processes.
Representatives of the few inert ingredients with graded HLB values are hydrogenated edible fats, which are available under the trade name of Gelucires, or the sorbitol esters of fatty acids, which are known for example, as Span. However, these also do not cover the broad HLB range from I to 16.
With the classical, fusible inert ingredients, the release rates can be varied only by the retarding agent selected or by the amount of this agent.
Frequently, a binder can be processed only in combination with a different fusible binder, such as polyethylene glycol, since its granulate-forming alone is inadequate. These binders also require the addition of lubricants or mold release agents. Some have a wax-like consistency. In the case of the known methods of melt granulation, the resulting, solidified granulates must frequently be subjected to an expensive screening process to comminute the product.
When preparing controlled release compositions by a coating procedure, destruction of the film coating is frequently observed during pressing because of the partially brittle, but also relatively thin film coatings, unless such a destruction is counteracted with a relatively large amount of external phase. When the film coating is destroyed, the release rate of active ingredient from the tablets is increased. This means that the release of active ingredient from these tablets mostly depends on the pressing force. Frequently, in the case of this method, the release of active ingredient is adjusted by the amount sprayed on during the manufacturing process. Depending on the film formation and the porosity, the release rate of active ingredient may change during storage, for example, due to post-curing.
Brief description of the drawing The invention is illustrated through the Examples and the appended drawing in which Figs. 1-21b illustrate properties of compositions as prepared by the Examples.
Description of the invention It is therefore an objective of the present invention to make oral pharmaceutical formulations available with a variable, adjustable release behavior, which can range from rapid to retarded. The release rate of the active ingredient of the dosage forms that are modified or retarded, is possible to produce non-disintegrating drug forms (so-called "single units") as well as suitably rapidly disintegrating and modified or retarded drug forms (so-called "multiple unit forms") from the granulates.
It is a further object of the present invention to provide methods for producing such retard or slow release formulations especially by melt granulation or melt pelletization.
According to the present invention, new oral pharmaceutical formulations with variably adjustable release behavior are provided which, in addition to one or more active ingredients, contain one or more sucrose esters of fatty acids as the sole release-controlling agent. The new pharmaceutical formulations are dosage forms, which release at various rates from immediate to controlled release.
As used throughout the disclosure and the claims, any reference to any active ingredient is meant also to include optionally more than one active ingredient, and reference to a sucrose ester of a fatty acid also includes optionally more than one sucrose ester of a fatty acid.
The pharmaceutical formulations of the present invention can be administered in the form of granules, pellets, tablets, film-coated tablets, microtablets, sugar-coated tablets and capsules and as therapeutic systems.
Surprisingly, sucrose esters of fatty acids are able to control the release of active ingredients in the desired manner and, moreover, to improve the technological properties during the preparation of the formulations of the invention by melt granulation or melt pelletization.
Sucrose esters of fatty acids are also suitable for granulating the active ingredient without the addition of other inert materials. By these means, a gross reduction in weight is possible in comparison to other methods, in which several fusible retarding agents or binders have to be used. At the same time, sucrose esters of fatty acids, particularly stearates with a low HLB value, such as from about I to about 16 can be suitably used as lubricants and as mold release agents.
Sucrose esters of fatty acids are nonionic surfactants, which are mono-, di-, tri- and polyesters of sucrose as the hydrophilic component and saturated or unsaturated fatty acids as the lipophilic component. By varying the degree of esterification and the nature of the fatty acids, sucrose esters of fatty acids can be produced with different HLB values, which have an effect on the biopharmaceutical properties, especially the release of active ingredient, the stability of the pharmaceutical formulation produced and its technological behavior. They are nontoxic, biodegradable, tasteless and odorless and have a long shelf life. The sucrose esters of fatty acids with a melting point higher than 30 C are solid at room temperature and have an HLB
value of fromlto16.
Sucrose esters of fatty acids are also sold under the name, for example, of sugar esters or sucrose esters by Mitsubishi (under the trade name of Ryoto), Gattefosse, or Sisterna and others.
Sucrose esters of fatty acids known from the literature are, for example, those of U.S. patent No. 4,844,067 used to improve the surface of silk fibers, and those of WO 93/17667 as taste improvers in pharmaceutical preparations.
Their main use is in the food industry. For example, sucrose esters of fatty acids are used to improve the mixing of chewing gum compositions, to counteract demixing and denaturing of finished beverages, for refining sugar, in condensed milk and in coffee creamers.
Sucrose esters of fatty acids are used for the production of wheat flour products, for example, as stabilizers to improve the texture and to avoid baking on and sticking on. In milk products they are used to stabilize emulsions and to avoid proteins and degradation, sucrose esters of fatty acids improve the crystallization behavior, and are effective emulsifiers and lower the viscosity during the production all fats and oils.
In U.S. patents Nos. 3,896,238; 4,150,114; and 4,046,886; the use of sucrose esters of fatty acids in combination with alkyl sulfoxide or phosphorus oxides in pharmaceutical compositions is disclosed for improving the penetration of the active substance through the skin. Sucrose monooctonate, monolaurate, monopalmitate and monostearate, as well as diesters and triesters of these compounds are named as special sucrose esters of fatty acids. In Japanese patent No. 8,175,437, the use of sucrose esters of fatty acids with an HLB value of 1 to 5 is disclosed as a base for suppositories.
In WO 88/06880, the use of sucrose esters of fatty acids in topical applications is disclosed, mixtures of mono- and dialkyl sucrose esters with an HLB value of 8 to 16 being used to improve the penetration through the skin. Preferably, sucrose cocoate, sucrose ricinoleate, sucrose laurate and sucrose stearate are used for that purpose.
Sucrose esters of fatty acids are also used, particularly, in cosmetic products (French patent No. 2,421,605, and Japanese patents Nos. 8,124,034 and 8,155, 306).
In German patent No. 4,003,844, pharmaceutical compositions are described which, in addition to the active ingredient, cyclosporin, contain a sucrose monoester of a fatty acid and a diluent or carrier. These compositions enable the cyclosporin dosage level, required for achieving an effective therapy, to be reduced and, thus, lead to a reduction in undesirable side effects. As sucrose monoester of a fatty acid, monoesters of C614 and Cg_tg fatty acids are particularly suitable for that purpose.
In WO 93/00093, a new controlled release formulation for Diltiazem in the form of spheroids is disclosed, which is composed of the active ingredient, a wetting agent and a polymer coating for controlling the release. Sucrose esters of fatty acids are used as a wetting agent. The actual retardation of active release takes place by a polymer.
Moreover, the wetting agent is processed with the active ingredients by extrusion or by granulation with organic solvents. The extrudates are coated with conventional polymers.
Sucrose or xylose esters of C1z_20 fatty acids, for example, are named as wetting agents.
In German patent No. 19,840,152, a retard formulation is disclosed, which contains calcium valproate, at least one acrylic polymer and at least one sugar ester, wherein the desired retarding effect being achieved by the acrylic polymer that is used. It is shown that the sugar ester, by itself, does not have any meaningful release retarding effect.
The suitability of sucrose esters of fatty acids to be the sole release-controlling agent in the pharmaceutical formulations of the present invention was all the more surprising, since these sucrose esters of fatty acids, on the one hand, have already been known for a long time per se, and now in accordance with the present invention can be employed in a simple manner in oral pharmaceutical formulations, with a variably adjustable release behavior.
The sucrose esters of fatty acids, used pursuant to the present invention, are esters of sucrose with saturated or unsaturated fatty acids or mixtures thereof.
Particularly suitable are C,Z_zZ fatty acids. Sucrose stearates, sucrose palmitates, sucrose laurates, sucrose behenates and sucrose oleates, with an HLB value of about I
to about 16, are suitably used. The melting point or melting range of the sucrose esters of fatty acids, which are used pursuant to the invention, lies between about 30 C and about 200 C. Suitably, sucrose esters of fatty acids with a melting point or melting range of from about 40 C to about 150 C are used.
An essential advantage of the present invention is that the desired release behavior of the new pharmaceutical formulations can be controlled by the type and proportion of the sucrose fatty acid ester or esters used and by the parameters of the manufacturing process. Selection of an appropriate ester or combination of esters, and suitable processing parameters can be determined as the basis of guidelines disclosed herein and by routine experimentation.
Sucrose esters of fatty acids with a low HLB value are suitable for achieving a retarded release. Sucrose esters of fatty acids with a high HLB
value are suitable for a more rapid or modified release behavior.
In the pharmaceutical formulations of the present invention, the sucrose esters of fatty acids can be used in amounts of from about 1% to about 95% by weight, based on the amount to be granulated (inner phase) in the formulation. More suitably, an amount of about 5% to about 50% by weight is used. Aside from sucrose esters of fatty acids, the active ingredient or mixtures of the active ingredient can also contain one or more inert excipients, such as are conventionally used in pharmaceutical preparations in the inner phase.
In further embodiments of the invention granules or pellets, which may or not contain sucrose esters of fatty acids in the granulate, can be coated instead with sucrose esters of fatty acids. The proportion of sucrose esters of fatty acids in the coating is from about 1% to about 60% by weight and suitably from about 3% to about 20% by weight, based on the coated form of the drug.
The sucrose esters of fatty acids can be used by themselves or optionally also in combination with other fusible inert ingredients. In some cases, the addition of one or more inert materials, such as plasticizers, can be of advantage for the process. A
further modification of the release of active ingredient is possible by way of embedding suitably during the melt granulating or melt pelletizing process, a so-called pore-forming agent, an inert material with certain properties, such as having a characteristic solubility or swellability.
As active ingredients, the inventive, oral pharmaceutical formulations can contain compounds, the solubility of which in water ranges from good to practically insoluble.
For example, active ingredients of the following indication groups were found to be suitable for this purpose, analeptic agents, antihypoxemic agents (such as caffeine), analgesics, antirheumatic agents (such as diclofenac, morphine, tramadol, tilidin, flupirtin), antiallergic agents (such as azelastin, pseudoephedrine), antiarrhythmic agents (such as quinidine, disopyramide, diltiazem, verapamil), antidementia agents (nootropic agents) (such as piracetam, nicergolin, xantino nicotinate, pentifyllin, vincamin), antidiabetic agents (such as glibenclamide), antiemetic agents, antivertiginous agents (such as betahistin dimesilate, dimenhydrinate), antiepilieptic agents (such as carbamazepine, valproic acid, calcium valproate dihydrate, retigabine), antihypertensive agents (such as talinolol, fosinopril, doxazosin, metoprolol, nifedipine), antihypotensive agents (such as norfenefrin-HCI, dihydroergotamine mesilate), broncholytic agents, antiasthmatic agents (such as salbutamol, terbutalin sulfate, theophyllin), diuretics (such as furosemide, piretanide), circulation promoters (such as buflomedil, naftidrofuryl, pentoxifyllin), hypnotic agents, cardiac agents (such as trinitroglycerin, isosorbid mononitrate, isosorbid dinitrate, molsidomin), sedatives, lipid-lowering agents (such as bezafibrate, fenofibrate, xantinol), antimigraine preparations (such as sumatriptan), muscle relaxants, anti-Parkinson agents and other agents against extrapyramidal disorders (such as levodopa, benserazide, carbi-dopa), psycho-pharmaceuticals (such as amitriptylin-HCI, venlafaxin-HCI, thioridazin-HCI, lithium carbonate, lithium acetate), or their pharmaceutically acceptable salts.
The pharmaceutical formulations of the present invention can suitably contain flupirtin, tramadol, nifedipine, carbamazepine, calcium valproate or retigabine.
Pursuant to the present invention, the pharmaceutical formulations of the invention can be suitably prepared by melt granulation or melt pelletization.
For this purpose, for example, the mixture of active ingredient and one or more sucrose esters of fatty acids is heated with stirring in a high-speed mixer, optionally together with other inert materials. The heating can be accomplished by a heating jacket, with microwave, by radiation energy or by supplying energy by stirring. Granulation commences when the melting temperature of the sucrose ester of the fatty acids used in the mixture is reached or when the surface of the mixture softens or commences to melt. Because of the agglomeration that commences and the increase in friction associated therewith, the power increases that is taken up by the stirrer motor. As a rule, the granulation is terminated when the power uptake commences to rise exponentially. After that, the warm melt granulate is either discharged from the mixture and cooled in thin layers at room temperature or cooled with suitable cooling means (such as a cooling jacket) in the mixer, possibly with stirring. Pursuant to the invention, it is also possible to add the sucrose esters of the fatty acids in the molten state.
Surprisingly, a very narrow distribution of granulate sizes is achieved during this process. Depending on the manner, in which the process is carried out, the granulate or pellet particles have an almost rounded and smooth surface.
Likewise, it is possible to use other equipment, which can be heated, such as a fluidized bed granulator, or a rotor granulator.
The granules, so produced, can optionally be classified through a screen, possibly mixed with inert ingredients of the outer phase and, for example, pressed into tablets, or filled into capsules.
The customary pharmaceutical disintegrants or disintegrating agents, fillers, mold release agents or the like are used as inert materials of the outer phase. Usually, the use of mold release agents can be omitted when sucrose stearates of low HLB
value are used, since sucrose stearates with a low HLB themselves also represent good mold release properties.
Accordingly, depending on the pharmaceutical, technological objective, rapidly releasing formulations and formulations, the release from which is modified to retarded (multiple units or single units), can be produced.
It was moreover surprisingly found that the sucrose esters of fatty acids are suitable as inert ingredients for hot melt coating. For this purpose, an amount of sucrose esters of fatty acids of the same or of a different type is added once again to a melt granulate, which has already been produced and solidified and the mixture is heated once again above the melting point or the softening temperature of the sucrose ester of the fatty acids added. The sucrose ester of the fatty acids is coated over the melt granulate at the same time. The coating process can also take place in the presence of a plasticizer.
Likewise, granulates, which are free of sucrose esters of fatty acids or pure active ingredients can be coated in the manner described.
The advantage of this method is that, on the one hand, a sufficient control of the release, particularly a retardation, can be attained already by coating with smaller amounts of the sucrose esters of fatty acids. On the other hand, the surface of the granules or pellets, so prepared is smoothened.
A further advantage is that by this method coatings, which are resistant to gastric juices, can be produced in a simple manner. Thus, the possibility exists that the release of active ingredient in the acid range of the pH can be greatly retarded because the sucrose ester of fatty acids is practically insoluble in aqueous and acidic media.
Powder coating represents a special form of hot melt coating. On the one hand, the readily flowable sucrose esters of fatty acids are added with the help of a suitable powder feeder, and on the other hand, a plasticizer, such as triethyl citrate is added to the starting materials. This method is distinguished by large cost and time savings, since drying processes, such as those employed in conventional aqueous methods, are not required. In particular, the so prepared pharmaceutical formulations are suitable for water-sensitive active ingredients, such as Na valproate.
The following examples further explain the present invention in greater detail.
Example 1:
Tramadol Hvdrochloride with 50% Sucrose Stearate with an HLB of I
- Formulation:
Substance Amount Tramadol hydrochloride 400 g Sucrose stearate S-170 400 g - Parameters:
Amount formulated 800 g impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 5 5. 0 C
The starting materials are heated with stirring in an high shear mixer of the GP1 type of firm Aeromatic-Fielder at the appropriate jacket temperature. The granulation commences when the product reaches a particular temperature. When the increase in the power uptake is reached and there is a sudden increase in the product temperature, the granulation is discontinued and the product is discharged, screened at a mesh width of 1.4 mm and cooled to room temperature.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in %
in 0.1 N HCl 74.03 89.40 95.75 95.57 97.61 98.58 97.87 In buffer of pH 6.8 78.99 89.29 93.99 93.37 94.26 96.5 96.88 Active Ingredient Release: see Fig. 1 Example 2:
Flupirtin maleate with 30% sucrose stearate of HLB 1 - Formulation:
Substance Amount Flupirtin maleate 240.0 g Sucrose stearate S-170 102.9 g - Parameters:
Amount of Formulation 342.9 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 61.2 C
- Produced as in Example 1 Example 3:
Nifedipine with 30% sucrose stearate of HLB 1 - Formulation:
Substance Amount Nifedipine 560 g Sucrose stearate S-170 240 g - Parameters:
Amount of Formulation 800 g Stirrer speed 700 rpm Chopper speed 3000 rpm Mantle temperature 58 C
- Produced as in Example 1 - Evaluation: Active Ingredient Release Time in hours 1 2 4 6 8 24 Release in % 2.14 3.76 5.84 8.42 10.72 25.91 in purified water/1.25% SDS
- Active Ingredient Release: see Fig. 2 Example 4:
Nifedipine with 30% sucrose palmitate of HLB 1 - Formulation:
Substance Amount Nifedipine 560 g Sucrose palmitate P-170 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Preparation as in Example I
- Evaluation: Active Ingredient Release Time in hours 1 2 4 6 8 24 Release in % 4.08 7.32 11.5 16.65 21.71 49.04 in purified water/1.25% SDS
For Active Ingredient Release, see Fig. 3 Example 5:
Tablets from melt granulate of nifedipine and 30% sucrose stearate of HLB 5 - Formulation:
Substance Amount Nifedipine 560 g Sucrose stearate P- 170 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 70 C
- Produced as in Example 1 - Parameters for tableting:
Subsequently, the granulate was pressed with a circular tableting tool with a diameter of 6 mm with medium convexity into tablets with a gross weight of 71.4 mg.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in % in purified 19.85 42.44 78.30 96.61 102.88 water/1.25% SDS
- Active Ingredient Release: see Fig. 4 Example 6:
Tablets from melt granulate of nifedipine with 50% sucrose stearate of HLB 9 and 2.5%
sucrose stearate of HLB I
- Formulation:
Substance Amount Nifedipine 400 g Sucrose stearate S-970 380 g Sucrose stearate S-170 20 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Produced according to Example 1 - Parameters for tableting:
Subsequently, the granulate was pressed with a circular tableting tool with a diameter of 6 mm with medium convexity into tablets with a gross weight of 100 mg.
- Evaluation of Active Ingredients Release:
Time in min 30 60 120 180 240 Release in % 20.10 40.37 73.26 94.14 102.93 in purified water/1.25% SDS
Active Ingredient Release: see Fig. 5 Example 7:
Carbamazepine with 10% sucrose stearate of HLB I
- Formulation:
Substance Amount Carbamazepine 720 g Sucrose stearate S-170 80 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 10.68 20.06 38.08 51.45 62.47 73.89 81.58 in modified intestinal juice Active Ingredient Release: see Fig. 6 Example 8:
Carbamazepine with 30% sucrose stearate of HLB 9 - Formulation:
Substance Amount Carbamazepine 560 g Sucrose stearate S-970 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 68 C
- Prepared according to Example I
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 26.09 42.27 62.65 80.58 87.38 96.56 100.84 in modified intestinal juice Active Ingredient Release: see Fig. 7 Example 9:
Carbamazepine with 50% sucrose behenate of HLB 3 and 2.5% triethyl citrate - Formulation:
Substance Amount Carbamazepine 400 g Sucrose behenate B-370 380 g Triethyl citrate 20 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 50 C
The starting materials, carbamazepine and triethyl citrate, are mixed in an intensive mixer of the GP 1 type of firm Aeromatic-Fielder. After a mixing time of 1 minute, sucrose behenate B- 370 is added and the mixture is heated with stirring at a heater jacket temperature of 50.0 C. When a particular product temperature is reached, at which an increase in power may be noted, the granulate is added to a screen with a mesh width of 1.4 mm and cooled to room temperature.
Example 10:
Tablets of a melt granulate of carbamazepine with 30% sucrose stearate of HLB
- Formulation:
Substance Amount Carbamazepine 560 g Sucrose stearate S-970 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 68 C
- Prepared according to Example 1 - Parameters for tableting:
The granulate is pressed without further additions with a round tableting tool with a diameter of 13 mm into flat tablets with a gross weight of 571 mg and a crush strength of 25 N.
- Evaluation: Release of Active Ingredient Time in min 30 60 120 180 240 360 480 Release in % in 5.36 8.04 13.78 17.89 21.01 27.31 32.08 modified intestinal juice Active Ingredient Release: see Fig. 8 Example 11:
Carbamazepine with 20% sucrose stearate of HLB 2 - Formulation:
Substance Amount Carbamazepine 640 g Sucrose stearate S-270 160 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 54 C
- Prepared as in Example 1 Example 12:
Calcium valproate dihydrate with 35% calcium hydrogen phosphate and 30%
sucrose stearate of HLB 1 - Formulation:
Substance Amount Calcium valproate dihydrate 280 g Calcium hydrogen phosphate 280 g Sucrose stearate S-170 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 53 C
- Preparation as in Example 1, the active ingredient calcium valproate dihydrate and calcium hydrogen phosphate being added to the mixer.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 64.89 75.63 85.02 Release in % in pH 6.8 36.85 61.26 71.60 Active Ingredient Release: see Fig. 9 Example 13:
Tablets from melt granulate of calcium valproate dihydrate and 30% sucrose stearate of - Formulation:
Substance Amount Calcium valproate dihydrate 560 g Sucrose stearate S-170 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Parameters for tableting:
The granulate is pressed with an oblong tableting tool, 23 mm long, 9 mm wide, into oblong tablets with a gross weight of 951 mg and crush strength of 65 N.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 4.96 9.14 13.66 Release in % in pH 6.8 92.93 98.57 99.43 Prepared according to Example 10 Example 14:
Tablets from melt granulate of calcium valproate dihydrate and 30% sucrose stearate of - Formulation:
Substance Amount Calcium valproate dihydrate 560 g Sucrose stearate S-970 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Preparation as in Example 1 - Parameters for tableting:
The granulate is pressed with an oblong tableting tool, 23 mm long, 9 mm wide, into oblong tablets with a gross weight of 951 mg and crush strength of 50 N.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 16.89 56.55 87.96 Release in % in pH 6.8 1.75 2.77 4.34 Active Ingredient Release: see Fig. 11 a For a comparison of the Active Ingredient Release of calcium valproate formulations at a pH of 3.0, see Fig. 11 b.
For a comparison of the Active Ingredient Release of calcium valproate formulations at a pH of 6.8, see Fig. 11 c.
Example 15:
Retigabine with 20% sucrose stearate of HLB 1 - Formulation:
Substance Amount Retigabine 800 g Sucrose stearate S-170 200 g - Parameters:
Amount of formulation 1000 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 37.23 46.71 75.81 in 0.1 N HCI
In a buffer at a pH of 5.71 8.77 13.82 15.79 23.60 27.99 35.62 6.8/1% Texapon Active Ingredient Release: see Fig. 12 Example 16:
Retigabine with 20% sucrose stearate of HLB 2 - Formulation:
Substance Amount Retigabine 400 g Sucrose stearate S-270 100 g - Parameters:
Amount of formulation 500 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 15 30 60 120 180 240 360 480 Release in % in 42.28 62.58 83.53 100.97 0.1NHCl Release in % in 11.82 20.77 34.41 44.94 52.74 61.63 66.37 buffer of pH 7.5 Active Ingredient Release: see Fig. 13 Example 17:
Retigabine with 20% sucrose stearate of HLB 1 and 10% sucrose stearate of HLB
- Formulation:
Substance Amount Retigabine 210 g Sucrose stearate S-170 60 g Sucrose stearate S-970 30 g - Parameters:
Amount of formulation 300 g Impeller speed 500 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Preparation as in Example 1 - Evaluation: Active Ingredient Release:
Time in min 15 30 60 120 180 240 360 480 Release in % in 71.49 85.13 97.93 102.82 0.1 N HCl Release in % in 31.02 36.93 51.97 61.25 70.63 79.01 78.77 a buffer of pH
6.8 Active Ingredient Release: see Fig. 14 a For a comparison of the Active Ingredient Release from Retigabine formulations in 0.1 N
HCI, see Fig. 14 b For a comparison of the Active Ingredient Release from Retigabine formulations in a buffer of pH 6.8, see Fig. 14 c Example 18:
Tablets of melt granulate with retigabine, 20% sucrose stearate of HLB 1 and 10%
croscarmelose sodium - Formulation:
Substance Amount Retigabine 800 g Sucrose stearate S-170 200 g - Parameters for granulating:
Amount of formulation 1000 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Prepared according to Example I
- Parameters for tableting:
Substance Amount Retigabine retard - granulate (see 270 g above) Croscarmellose sodium 30 g The tableting mixture is pressed into tablets with a round tableting tool with a diameter of 9 mm, a bevel of 45 , and a radius of curvature R13.
- Evaluation: Active Ingredient Release Time in min 15 30 60 120 180 240 360 480 Release in % 40.76 81.59 96.13 100.76 in0.1 NHCI
In a buffer of pH 6,8 22.20 29.80 38.95 46.49 53.58 60.85 64.69 / 1% sodium dodecyl sulfate (SDS) Active Ingredient Release: see Fig. 15 Example 19:
Retip,abine with 7% sucrose stearate of HLB 1 - Formulation:
Substance Amount Retigabine 372 g Sucrose stearate S-170 28 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 C
In an high shear mixer of the GP I type of firm Aeromatic-Fielder, the starting materials are heated with stirring at a mantle temperature of 50.0 C in a special bowl, which is provided with a PTFE in-liner. After the power consumption uptake has increased once again, the pellets are removed and cooled to room temperature in thin layers.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in a buffer 16.62 29.85 50.39 67.14 69.35 83.20 90.96 ofpH7.5/2.5 SDS
Active Ingredient Release: see Fig. 16 Example 20:
Retip,abine with 20% sucrose stearate of HLB 11 - Formulation:
Substance Amount Retigabine 320 g Sucrose stearate S-1170 80 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 - 1100 rpm Heater jacket temp. 50 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 49.91 79.95 100.81 106.03 104.36 pH 7.5 / 2.5% SDS
Active Ingredient Release: see Example 17 Example 21:
Retigabine with 20% sucrose stearate of HLB 16 - Formulation:
Substance Amount Retigabine 320 g Sucrose stearate S-1170 80 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 - 1100 rpm Heater jacket temp. 50 - 55 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 41.77 68.71 92.32 99.95 101.47 pH7.5/2.5%SDS
Active Ingredient Release: see Fig. 18 Example 22:
Retigabine with 16% sucrose stearate of HLB 15 - Formulation:
Substance Amount Retigabine 336 g Sucrose stearate S-1570 64 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 - 60 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 64.67 89.83 99.98 101.78 100.99 pH7.5/2.5%SDS
Active Ingredient Release: see Fig. 19 Example 23:
Retigabine tablets - Formulation melt granulate:
Substance Amount Retigabine 332 g Sucrose stearate S-1570 68 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 - 60 C
- Prepared as in Example 19 - Coating formulation:
Substance Amount Retigabine - melt granulate with 1000 g 17% sucrose stearate of HLB 15 Eudragit L 30 D-55 400 g (corresponds to 120 g of lacquer solids) Talcum 60 g Triethyl citrate 12 g The melt granulates from 5 batches are combined and sprayed in a rotor granulator with an inflow of air at 50 C at 300 rpm with a suspension of Eudragit L 30 D-55, talcum and triethyl citrate in 536 g of purified water. This is followed by drying up to a product temperature of 33 C.
The granulate, so coated, is homogenized for 10 minutes in a Turbula with 30% by weight of microcrystalline cellulose and 5% by weight of croscarmellose sodium.
The tableting mixture is pressed into oblong 17 x 8 mm, curved tablets with an average crush strength of 87 N.
Time in min 15 30 60 120 180 240 Release in % in 50.3 68.8 83 88.3 0.1 N HCl In a buffer of pH 7.5 / 16.1 30.4 55.7 83.4 95.2 99.2 1.7% SDS
Active Ingredient Release in 0. 1 N HCI: see Fig. 20 a Active Ingredient Release in a buffer of 7.5, 1.7% SDS: see Fig. 20 b Example 24:
Hot melt coating of retigabine melt granulate with 10% sucrose stearate of HLB
- Formulation of coated melt granulate:
Substance Amount Retigabine melt granulate 500 g (90% by weight of retigabine and 10% by weight of sucrose stearate S-170) Sucrose stearate S-170 55.6 g - Parameters:
Amount of formulation 555.6 g Impeller speed 700 rpm Heater jacket temp. 52 C
In a high shear mixer of the GP I type of the firm Aeromatic-Fielder, the retigabine melt granulate is heated with stirring at a heater jacket temperature of 52 C. At a product temperature of 30 C, sucrose stearate S- 170 is added and granulated for a further 7 minutes with the chopper switched on (3000 rpm). The coated granulate was removed and screened through a 1.4 mm mesh screen.
- Results: particle size distribution Particle size ( m) Percentage (%) > 1000 3.4 > 800 4.0 > 500 34.4 > 315 40.9 > 160 14.0 > 50 3.4 < 50 0 Time in min 15 30 60 120 180 240 360 480 Release in % in 23.8 43.6 71.4 94.4 0.1 N HCl In a buffer of pH 7.2 13.2 19.8 25.4 31 40.2 47.4 7.5/2.5%SDS
Active Ingredient Release in 0.1N HCI: see Fig. 21 a Active Ingredient Release in a buffer of pH 7.5, 2.5% SDS: see Fig. 21b
Description of the invention It is therefore an objective of the present invention to make oral pharmaceutical formulations available with a variable, adjustable release behavior, which can range from rapid to retarded. The release rate of the active ingredient of the dosage forms that are modified or retarded, is possible to produce non-disintegrating drug forms (so-called "single units") as well as suitably rapidly disintegrating and modified or retarded drug forms (so-called "multiple unit forms") from the granulates.
It is a further object of the present invention to provide methods for producing such retard or slow release formulations especially by melt granulation or melt pelletization.
According to the present invention, new oral pharmaceutical formulations with variably adjustable release behavior are provided which, in addition to one or more active ingredients, contain one or more sucrose esters of fatty acids as the sole release-controlling agent. The new pharmaceutical formulations are dosage forms, which release at various rates from immediate to controlled release.
As used throughout the disclosure and the claims, any reference to any active ingredient is meant also to include optionally more than one active ingredient, and reference to a sucrose ester of a fatty acid also includes optionally more than one sucrose ester of a fatty acid.
The pharmaceutical formulations of the present invention can be administered in the form of granules, pellets, tablets, film-coated tablets, microtablets, sugar-coated tablets and capsules and as therapeutic systems.
Surprisingly, sucrose esters of fatty acids are able to control the release of active ingredients in the desired manner and, moreover, to improve the technological properties during the preparation of the formulations of the invention by melt granulation or melt pelletization.
Sucrose esters of fatty acids are also suitable for granulating the active ingredient without the addition of other inert materials. By these means, a gross reduction in weight is possible in comparison to other methods, in which several fusible retarding agents or binders have to be used. At the same time, sucrose esters of fatty acids, particularly stearates with a low HLB value, such as from about I to about 16 can be suitably used as lubricants and as mold release agents.
Sucrose esters of fatty acids are nonionic surfactants, which are mono-, di-, tri- and polyesters of sucrose as the hydrophilic component and saturated or unsaturated fatty acids as the lipophilic component. By varying the degree of esterification and the nature of the fatty acids, sucrose esters of fatty acids can be produced with different HLB values, which have an effect on the biopharmaceutical properties, especially the release of active ingredient, the stability of the pharmaceutical formulation produced and its technological behavior. They are nontoxic, biodegradable, tasteless and odorless and have a long shelf life. The sucrose esters of fatty acids with a melting point higher than 30 C are solid at room temperature and have an HLB
value of fromlto16.
Sucrose esters of fatty acids are also sold under the name, for example, of sugar esters or sucrose esters by Mitsubishi (under the trade name of Ryoto), Gattefosse, or Sisterna and others.
Sucrose esters of fatty acids known from the literature are, for example, those of U.S. patent No. 4,844,067 used to improve the surface of silk fibers, and those of WO 93/17667 as taste improvers in pharmaceutical preparations.
Their main use is in the food industry. For example, sucrose esters of fatty acids are used to improve the mixing of chewing gum compositions, to counteract demixing and denaturing of finished beverages, for refining sugar, in condensed milk and in coffee creamers.
Sucrose esters of fatty acids are used for the production of wheat flour products, for example, as stabilizers to improve the texture and to avoid baking on and sticking on. In milk products they are used to stabilize emulsions and to avoid proteins and degradation, sucrose esters of fatty acids improve the crystallization behavior, and are effective emulsifiers and lower the viscosity during the production all fats and oils.
In U.S. patents Nos. 3,896,238; 4,150,114; and 4,046,886; the use of sucrose esters of fatty acids in combination with alkyl sulfoxide or phosphorus oxides in pharmaceutical compositions is disclosed for improving the penetration of the active substance through the skin. Sucrose monooctonate, monolaurate, monopalmitate and monostearate, as well as diesters and triesters of these compounds are named as special sucrose esters of fatty acids. In Japanese patent No. 8,175,437, the use of sucrose esters of fatty acids with an HLB value of 1 to 5 is disclosed as a base for suppositories.
In WO 88/06880, the use of sucrose esters of fatty acids in topical applications is disclosed, mixtures of mono- and dialkyl sucrose esters with an HLB value of 8 to 16 being used to improve the penetration through the skin. Preferably, sucrose cocoate, sucrose ricinoleate, sucrose laurate and sucrose stearate are used for that purpose.
Sucrose esters of fatty acids are also used, particularly, in cosmetic products (French patent No. 2,421,605, and Japanese patents Nos. 8,124,034 and 8,155, 306).
In German patent No. 4,003,844, pharmaceutical compositions are described which, in addition to the active ingredient, cyclosporin, contain a sucrose monoester of a fatty acid and a diluent or carrier. These compositions enable the cyclosporin dosage level, required for achieving an effective therapy, to be reduced and, thus, lead to a reduction in undesirable side effects. As sucrose monoester of a fatty acid, monoesters of C614 and Cg_tg fatty acids are particularly suitable for that purpose.
In WO 93/00093, a new controlled release formulation for Diltiazem in the form of spheroids is disclosed, which is composed of the active ingredient, a wetting agent and a polymer coating for controlling the release. Sucrose esters of fatty acids are used as a wetting agent. The actual retardation of active release takes place by a polymer.
Moreover, the wetting agent is processed with the active ingredients by extrusion or by granulation with organic solvents. The extrudates are coated with conventional polymers.
Sucrose or xylose esters of C1z_20 fatty acids, for example, are named as wetting agents.
In German patent No. 19,840,152, a retard formulation is disclosed, which contains calcium valproate, at least one acrylic polymer and at least one sugar ester, wherein the desired retarding effect being achieved by the acrylic polymer that is used. It is shown that the sugar ester, by itself, does not have any meaningful release retarding effect.
The suitability of sucrose esters of fatty acids to be the sole release-controlling agent in the pharmaceutical formulations of the present invention was all the more surprising, since these sucrose esters of fatty acids, on the one hand, have already been known for a long time per se, and now in accordance with the present invention can be employed in a simple manner in oral pharmaceutical formulations, with a variably adjustable release behavior.
The sucrose esters of fatty acids, used pursuant to the present invention, are esters of sucrose with saturated or unsaturated fatty acids or mixtures thereof.
Particularly suitable are C,Z_zZ fatty acids. Sucrose stearates, sucrose palmitates, sucrose laurates, sucrose behenates and sucrose oleates, with an HLB value of about I
to about 16, are suitably used. The melting point or melting range of the sucrose esters of fatty acids, which are used pursuant to the invention, lies between about 30 C and about 200 C. Suitably, sucrose esters of fatty acids with a melting point or melting range of from about 40 C to about 150 C are used.
An essential advantage of the present invention is that the desired release behavior of the new pharmaceutical formulations can be controlled by the type and proportion of the sucrose fatty acid ester or esters used and by the parameters of the manufacturing process. Selection of an appropriate ester or combination of esters, and suitable processing parameters can be determined as the basis of guidelines disclosed herein and by routine experimentation.
Sucrose esters of fatty acids with a low HLB value are suitable for achieving a retarded release. Sucrose esters of fatty acids with a high HLB
value are suitable for a more rapid or modified release behavior.
In the pharmaceutical formulations of the present invention, the sucrose esters of fatty acids can be used in amounts of from about 1% to about 95% by weight, based on the amount to be granulated (inner phase) in the formulation. More suitably, an amount of about 5% to about 50% by weight is used. Aside from sucrose esters of fatty acids, the active ingredient or mixtures of the active ingredient can also contain one or more inert excipients, such as are conventionally used in pharmaceutical preparations in the inner phase.
In further embodiments of the invention granules or pellets, which may or not contain sucrose esters of fatty acids in the granulate, can be coated instead with sucrose esters of fatty acids. The proportion of sucrose esters of fatty acids in the coating is from about 1% to about 60% by weight and suitably from about 3% to about 20% by weight, based on the coated form of the drug.
The sucrose esters of fatty acids can be used by themselves or optionally also in combination with other fusible inert ingredients. In some cases, the addition of one or more inert materials, such as plasticizers, can be of advantage for the process. A
further modification of the release of active ingredient is possible by way of embedding suitably during the melt granulating or melt pelletizing process, a so-called pore-forming agent, an inert material with certain properties, such as having a characteristic solubility or swellability.
As active ingredients, the inventive, oral pharmaceutical formulations can contain compounds, the solubility of which in water ranges from good to practically insoluble.
For example, active ingredients of the following indication groups were found to be suitable for this purpose, analeptic agents, antihypoxemic agents (such as caffeine), analgesics, antirheumatic agents (such as diclofenac, morphine, tramadol, tilidin, flupirtin), antiallergic agents (such as azelastin, pseudoephedrine), antiarrhythmic agents (such as quinidine, disopyramide, diltiazem, verapamil), antidementia agents (nootropic agents) (such as piracetam, nicergolin, xantino nicotinate, pentifyllin, vincamin), antidiabetic agents (such as glibenclamide), antiemetic agents, antivertiginous agents (such as betahistin dimesilate, dimenhydrinate), antiepilieptic agents (such as carbamazepine, valproic acid, calcium valproate dihydrate, retigabine), antihypertensive agents (such as talinolol, fosinopril, doxazosin, metoprolol, nifedipine), antihypotensive agents (such as norfenefrin-HCI, dihydroergotamine mesilate), broncholytic agents, antiasthmatic agents (such as salbutamol, terbutalin sulfate, theophyllin), diuretics (such as furosemide, piretanide), circulation promoters (such as buflomedil, naftidrofuryl, pentoxifyllin), hypnotic agents, cardiac agents (such as trinitroglycerin, isosorbid mononitrate, isosorbid dinitrate, molsidomin), sedatives, lipid-lowering agents (such as bezafibrate, fenofibrate, xantinol), antimigraine preparations (such as sumatriptan), muscle relaxants, anti-Parkinson agents and other agents against extrapyramidal disorders (such as levodopa, benserazide, carbi-dopa), psycho-pharmaceuticals (such as amitriptylin-HCI, venlafaxin-HCI, thioridazin-HCI, lithium carbonate, lithium acetate), or their pharmaceutically acceptable salts.
The pharmaceutical formulations of the present invention can suitably contain flupirtin, tramadol, nifedipine, carbamazepine, calcium valproate or retigabine.
Pursuant to the present invention, the pharmaceutical formulations of the invention can be suitably prepared by melt granulation or melt pelletization.
For this purpose, for example, the mixture of active ingredient and one or more sucrose esters of fatty acids is heated with stirring in a high-speed mixer, optionally together with other inert materials. The heating can be accomplished by a heating jacket, with microwave, by radiation energy or by supplying energy by stirring. Granulation commences when the melting temperature of the sucrose ester of the fatty acids used in the mixture is reached or when the surface of the mixture softens or commences to melt. Because of the agglomeration that commences and the increase in friction associated therewith, the power increases that is taken up by the stirrer motor. As a rule, the granulation is terminated when the power uptake commences to rise exponentially. After that, the warm melt granulate is either discharged from the mixture and cooled in thin layers at room temperature or cooled with suitable cooling means (such as a cooling jacket) in the mixer, possibly with stirring. Pursuant to the invention, it is also possible to add the sucrose esters of the fatty acids in the molten state.
Surprisingly, a very narrow distribution of granulate sizes is achieved during this process. Depending on the manner, in which the process is carried out, the granulate or pellet particles have an almost rounded and smooth surface.
Likewise, it is possible to use other equipment, which can be heated, such as a fluidized bed granulator, or a rotor granulator.
The granules, so produced, can optionally be classified through a screen, possibly mixed with inert ingredients of the outer phase and, for example, pressed into tablets, or filled into capsules.
The customary pharmaceutical disintegrants or disintegrating agents, fillers, mold release agents or the like are used as inert materials of the outer phase. Usually, the use of mold release agents can be omitted when sucrose stearates of low HLB
value are used, since sucrose stearates with a low HLB themselves also represent good mold release properties.
Accordingly, depending on the pharmaceutical, technological objective, rapidly releasing formulations and formulations, the release from which is modified to retarded (multiple units or single units), can be produced.
It was moreover surprisingly found that the sucrose esters of fatty acids are suitable as inert ingredients for hot melt coating. For this purpose, an amount of sucrose esters of fatty acids of the same or of a different type is added once again to a melt granulate, which has already been produced and solidified and the mixture is heated once again above the melting point or the softening temperature of the sucrose ester of the fatty acids added. The sucrose ester of the fatty acids is coated over the melt granulate at the same time. The coating process can also take place in the presence of a plasticizer.
Likewise, granulates, which are free of sucrose esters of fatty acids or pure active ingredients can be coated in the manner described.
The advantage of this method is that, on the one hand, a sufficient control of the release, particularly a retardation, can be attained already by coating with smaller amounts of the sucrose esters of fatty acids. On the other hand, the surface of the granules or pellets, so prepared is smoothened.
A further advantage is that by this method coatings, which are resistant to gastric juices, can be produced in a simple manner. Thus, the possibility exists that the release of active ingredient in the acid range of the pH can be greatly retarded because the sucrose ester of fatty acids is practically insoluble in aqueous and acidic media.
Powder coating represents a special form of hot melt coating. On the one hand, the readily flowable sucrose esters of fatty acids are added with the help of a suitable powder feeder, and on the other hand, a plasticizer, such as triethyl citrate is added to the starting materials. This method is distinguished by large cost and time savings, since drying processes, such as those employed in conventional aqueous methods, are not required. In particular, the so prepared pharmaceutical formulations are suitable for water-sensitive active ingredients, such as Na valproate.
The following examples further explain the present invention in greater detail.
Example 1:
Tramadol Hvdrochloride with 50% Sucrose Stearate with an HLB of I
- Formulation:
Substance Amount Tramadol hydrochloride 400 g Sucrose stearate S-170 400 g - Parameters:
Amount formulated 800 g impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 5 5. 0 C
The starting materials are heated with stirring in an high shear mixer of the GP1 type of firm Aeromatic-Fielder at the appropriate jacket temperature. The granulation commences when the product reaches a particular temperature. When the increase in the power uptake is reached and there is a sudden increase in the product temperature, the granulation is discontinued and the product is discharged, screened at a mesh width of 1.4 mm and cooled to room temperature.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in %
in 0.1 N HCl 74.03 89.40 95.75 95.57 97.61 98.58 97.87 In buffer of pH 6.8 78.99 89.29 93.99 93.37 94.26 96.5 96.88 Active Ingredient Release: see Fig. 1 Example 2:
Flupirtin maleate with 30% sucrose stearate of HLB 1 - Formulation:
Substance Amount Flupirtin maleate 240.0 g Sucrose stearate S-170 102.9 g - Parameters:
Amount of Formulation 342.9 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 61.2 C
- Produced as in Example 1 Example 3:
Nifedipine with 30% sucrose stearate of HLB 1 - Formulation:
Substance Amount Nifedipine 560 g Sucrose stearate S-170 240 g - Parameters:
Amount of Formulation 800 g Stirrer speed 700 rpm Chopper speed 3000 rpm Mantle temperature 58 C
- Produced as in Example 1 - Evaluation: Active Ingredient Release Time in hours 1 2 4 6 8 24 Release in % 2.14 3.76 5.84 8.42 10.72 25.91 in purified water/1.25% SDS
- Active Ingredient Release: see Fig. 2 Example 4:
Nifedipine with 30% sucrose palmitate of HLB 1 - Formulation:
Substance Amount Nifedipine 560 g Sucrose palmitate P-170 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Preparation as in Example I
- Evaluation: Active Ingredient Release Time in hours 1 2 4 6 8 24 Release in % 4.08 7.32 11.5 16.65 21.71 49.04 in purified water/1.25% SDS
For Active Ingredient Release, see Fig. 3 Example 5:
Tablets from melt granulate of nifedipine and 30% sucrose stearate of HLB 5 - Formulation:
Substance Amount Nifedipine 560 g Sucrose stearate P- 170 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 70 C
- Produced as in Example 1 - Parameters for tableting:
Subsequently, the granulate was pressed with a circular tableting tool with a diameter of 6 mm with medium convexity into tablets with a gross weight of 71.4 mg.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in % in purified 19.85 42.44 78.30 96.61 102.88 water/1.25% SDS
- Active Ingredient Release: see Fig. 4 Example 6:
Tablets from melt granulate of nifedipine with 50% sucrose stearate of HLB 9 and 2.5%
sucrose stearate of HLB I
- Formulation:
Substance Amount Nifedipine 400 g Sucrose stearate S-970 380 g Sucrose stearate S-170 20 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Produced according to Example 1 - Parameters for tableting:
Subsequently, the granulate was pressed with a circular tableting tool with a diameter of 6 mm with medium convexity into tablets with a gross weight of 100 mg.
- Evaluation of Active Ingredients Release:
Time in min 30 60 120 180 240 Release in % 20.10 40.37 73.26 94.14 102.93 in purified water/1.25% SDS
Active Ingredient Release: see Fig. 5 Example 7:
Carbamazepine with 10% sucrose stearate of HLB I
- Formulation:
Substance Amount Carbamazepine 720 g Sucrose stearate S-170 80 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 10.68 20.06 38.08 51.45 62.47 73.89 81.58 in modified intestinal juice Active Ingredient Release: see Fig. 6 Example 8:
Carbamazepine with 30% sucrose stearate of HLB 9 - Formulation:
Substance Amount Carbamazepine 560 g Sucrose stearate S-970 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 68 C
- Prepared according to Example I
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 26.09 42.27 62.65 80.58 87.38 96.56 100.84 in modified intestinal juice Active Ingredient Release: see Fig. 7 Example 9:
Carbamazepine with 50% sucrose behenate of HLB 3 and 2.5% triethyl citrate - Formulation:
Substance Amount Carbamazepine 400 g Sucrose behenate B-370 380 g Triethyl citrate 20 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 50 C
The starting materials, carbamazepine and triethyl citrate, are mixed in an intensive mixer of the GP 1 type of firm Aeromatic-Fielder. After a mixing time of 1 minute, sucrose behenate B- 370 is added and the mixture is heated with stirring at a heater jacket temperature of 50.0 C. When a particular product temperature is reached, at which an increase in power may be noted, the granulate is added to a screen with a mesh width of 1.4 mm and cooled to room temperature.
Example 10:
Tablets of a melt granulate of carbamazepine with 30% sucrose stearate of HLB
- Formulation:
Substance Amount Carbamazepine 560 g Sucrose stearate S-970 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 68 C
- Prepared according to Example 1 - Parameters for tableting:
The granulate is pressed without further additions with a round tableting tool with a diameter of 13 mm into flat tablets with a gross weight of 571 mg and a crush strength of 25 N.
- Evaluation: Release of Active Ingredient Time in min 30 60 120 180 240 360 480 Release in % in 5.36 8.04 13.78 17.89 21.01 27.31 32.08 modified intestinal juice Active Ingredient Release: see Fig. 8 Example 11:
Carbamazepine with 20% sucrose stearate of HLB 2 - Formulation:
Substance Amount Carbamazepine 640 g Sucrose stearate S-270 160 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 54 C
- Prepared as in Example 1 Example 12:
Calcium valproate dihydrate with 35% calcium hydrogen phosphate and 30%
sucrose stearate of HLB 1 - Formulation:
Substance Amount Calcium valproate dihydrate 280 g Calcium hydrogen phosphate 280 g Sucrose stearate S-170 240 g - Parameters:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 53 C
- Preparation as in Example 1, the active ingredient calcium valproate dihydrate and calcium hydrogen phosphate being added to the mixer.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 64.89 75.63 85.02 Release in % in pH 6.8 36.85 61.26 71.60 Active Ingredient Release: see Fig. 9 Example 13:
Tablets from melt granulate of calcium valproate dihydrate and 30% sucrose stearate of - Formulation:
Substance Amount Calcium valproate dihydrate 560 g Sucrose stearate S-170 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Parameters for tableting:
The granulate is pressed with an oblong tableting tool, 23 mm long, 9 mm wide, into oblong tablets with a gross weight of 951 mg and crush strength of 65 N.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 4.96 9.14 13.66 Release in % in pH 6.8 92.93 98.57 99.43 Prepared according to Example 10 Example 14:
Tablets from melt granulate of calcium valproate dihydrate and 30% sucrose stearate of - Formulation:
Substance Amount Calcium valproate dihydrate 560 g Sucrose stearate S-970 240 g - Parameters for granulating:
Amount of formulation 800 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Preparation as in Example 1 - Parameters for tableting:
The granulate is pressed with an oblong tableting tool, 23 mm long, 9 mm wide, into oblong tablets with a gross weight of 951 mg and crush strength of 50 N.
- Evaluation: Active Ingredient Release Time in min 60 240 480 Release in % in pH 3.0 16.89 56.55 87.96 Release in % in pH 6.8 1.75 2.77 4.34 Active Ingredient Release: see Fig. 11 a For a comparison of the Active Ingredient Release of calcium valproate formulations at a pH of 3.0, see Fig. 11 b.
For a comparison of the Active Ingredient Release of calcium valproate formulations at a pH of 6.8, see Fig. 11 c.
Example 15:
Retigabine with 20% sucrose stearate of HLB 1 - Formulation:
Substance Amount Retigabine 800 g Sucrose stearate S-170 200 g - Parameters:
Amount of formulation 1000 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in % 37.23 46.71 75.81 in 0.1 N HCI
In a buffer at a pH of 5.71 8.77 13.82 15.79 23.60 27.99 35.62 6.8/1% Texapon Active Ingredient Release: see Fig. 12 Example 16:
Retigabine with 20% sucrose stearate of HLB 2 - Formulation:
Substance Amount Retigabine 400 g Sucrose stearate S-270 100 g - Parameters:
Amount of formulation 500 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 55 C
- Prepared according to Example 1 - Evaluation: Active Ingredient Release Time in min 15 30 60 120 180 240 360 480 Release in % in 42.28 62.58 83.53 100.97 0.1NHCl Release in % in 11.82 20.77 34.41 44.94 52.74 61.63 66.37 buffer of pH 7.5 Active Ingredient Release: see Fig. 13 Example 17:
Retigabine with 20% sucrose stearate of HLB 1 and 10% sucrose stearate of HLB
- Formulation:
Substance Amount Retigabine 210 g Sucrose stearate S-170 60 g Sucrose stearate S-970 30 g - Parameters:
Amount of formulation 300 g Impeller speed 500 rpm Chopper speed 3000 rpm Heater jacket temp. 65 C
- Preparation as in Example 1 - Evaluation: Active Ingredient Release:
Time in min 15 30 60 120 180 240 360 480 Release in % in 71.49 85.13 97.93 102.82 0.1 N HCl Release in % in 31.02 36.93 51.97 61.25 70.63 79.01 78.77 a buffer of pH
6.8 Active Ingredient Release: see Fig. 14 a For a comparison of the Active Ingredient Release from Retigabine formulations in 0.1 N
HCI, see Fig. 14 b For a comparison of the Active Ingredient Release from Retigabine formulations in a buffer of pH 6.8, see Fig. 14 c Example 18:
Tablets of melt granulate with retigabine, 20% sucrose stearate of HLB 1 and 10%
croscarmelose sodium - Formulation:
Substance Amount Retigabine 800 g Sucrose stearate S-170 200 g - Parameters for granulating:
Amount of formulation 1000 g Impeller speed 700 rpm Chopper speed 3000 rpm Heater jacket temp. 52 C
- Prepared according to Example I
- Parameters for tableting:
Substance Amount Retigabine retard - granulate (see 270 g above) Croscarmellose sodium 30 g The tableting mixture is pressed into tablets with a round tableting tool with a diameter of 9 mm, a bevel of 45 , and a radius of curvature R13.
- Evaluation: Active Ingredient Release Time in min 15 30 60 120 180 240 360 480 Release in % 40.76 81.59 96.13 100.76 in0.1 NHCI
In a buffer of pH 6,8 22.20 29.80 38.95 46.49 53.58 60.85 64.69 / 1% sodium dodecyl sulfate (SDS) Active Ingredient Release: see Fig. 15 Example 19:
Retip,abine with 7% sucrose stearate of HLB 1 - Formulation:
Substance Amount Retigabine 372 g Sucrose stearate S-170 28 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 C
In an high shear mixer of the GP I type of firm Aeromatic-Fielder, the starting materials are heated with stirring at a mantle temperature of 50.0 C in a special bowl, which is provided with a PTFE in-liner. After the power consumption uptake has increased once again, the pellets are removed and cooled to room temperature in thin layers.
- Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 360 480 Release in a buffer 16.62 29.85 50.39 67.14 69.35 83.20 90.96 ofpH7.5/2.5 SDS
Active Ingredient Release: see Fig. 16 Example 20:
Retip,abine with 20% sucrose stearate of HLB 11 - Formulation:
Substance Amount Retigabine 320 g Sucrose stearate S-1170 80 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 - 1100 rpm Heater jacket temp. 50 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 49.91 79.95 100.81 106.03 104.36 pH 7.5 / 2.5% SDS
Active Ingredient Release: see Example 17 Example 21:
Retigabine with 20% sucrose stearate of HLB 16 - Formulation:
Substance Amount Retigabine 320 g Sucrose stearate S-1170 80 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 - 1100 rpm Heater jacket temp. 50 - 55 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 41.77 68.71 92.32 99.95 101.47 pH7.5/2.5%SDS
Active Ingredient Release: see Fig. 18 Example 22:
Retigabine with 16% sucrose stearate of HLB 15 - Formulation:
Substance Amount Retigabine 336 g Sucrose stearate S-1570 64 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 - 60 C
- Prepared according to Example 19 - Evaluation: Active Ingredient Release Time in min 30 60 120 180 240 Release in a buffer of 64.67 89.83 99.98 101.78 100.99 pH7.5/2.5%SDS
Active Ingredient Release: see Fig. 19 Example 23:
Retigabine tablets - Formulation melt granulate:
Substance Amount Retigabine 332 g Sucrose stearate S-1570 68 g - Parameters:
Amount of formulation 400 g Impeller speed 1300 rpm Heater jacket temp. 50 - 60 C
- Prepared as in Example 19 - Coating formulation:
Substance Amount Retigabine - melt granulate with 1000 g 17% sucrose stearate of HLB 15 Eudragit L 30 D-55 400 g (corresponds to 120 g of lacquer solids) Talcum 60 g Triethyl citrate 12 g The melt granulates from 5 batches are combined and sprayed in a rotor granulator with an inflow of air at 50 C at 300 rpm with a suspension of Eudragit L 30 D-55, talcum and triethyl citrate in 536 g of purified water. This is followed by drying up to a product temperature of 33 C.
The granulate, so coated, is homogenized for 10 minutes in a Turbula with 30% by weight of microcrystalline cellulose and 5% by weight of croscarmellose sodium.
The tableting mixture is pressed into oblong 17 x 8 mm, curved tablets with an average crush strength of 87 N.
Time in min 15 30 60 120 180 240 Release in % in 50.3 68.8 83 88.3 0.1 N HCl In a buffer of pH 7.5 / 16.1 30.4 55.7 83.4 95.2 99.2 1.7% SDS
Active Ingredient Release in 0. 1 N HCI: see Fig. 20 a Active Ingredient Release in a buffer of 7.5, 1.7% SDS: see Fig. 20 b Example 24:
Hot melt coating of retigabine melt granulate with 10% sucrose stearate of HLB
- Formulation of coated melt granulate:
Substance Amount Retigabine melt granulate 500 g (90% by weight of retigabine and 10% by weight of sucrose stearate S-170) Sucrose stearate S-170 55.6 g - Parameters:
Amount of formulation 555.6 g Impeller speed 700 rpm Heater jacket temp. 52 C
In a high shear mixer of the GP I type of the firm Aeromatic-Fielder, the retigabine melt granulate is heated with stirring at a heater jacket temperature of 52 C. At a product temperature of 30 C, sucrose stearate S- 170 is added and granulated for a further 7 minutes with the chopper switched on (3000 rpm). The coated granulate was removed and screened through a 1.4 mm mesh screen.
- Results: particle size distribution Particle size ( m) Percentage (%) > 1000 3.4 > 800 4.0 > 500 34.4 > 315 40.9 > 160 14.0 > 50 3.4 < 50 0 Time in min 15 30 60 120 180 240 360 480 Release in % in 23.8 43.6 71.4 94.4 0.1 N HCl In a buffer of pH 7.2 13.2 19.8 25.4 31 40.2 47.4 7.5/2.5%SDS
Active Ingredient Release in 0.1N HCI: see Fig. 21 a Active Ingredient Release in a buffer of pH 7.5, 2.5% SDS: see Fig. 21b
Claims (28)
1. An oral pharmaceutical formulation with variably adjustable release rate, which comprises a.) at least one active ingredient selected from the group consisting of caffeine, diclofenac, morphine, tramadol, tilidine, nicargoline, pentifylline, vincamine, flupirtine, azelastine, pseudoephedrine, calcium valproate, quinidine, disopyramide, diltiazem, verapamil, piracetam, nicergolin, xantino nicotinate, pentifyllin, vincamin, glibenclamide, betahistin dimesilate, dimenhydrinate, carbamazepine, valproic acid, calcium valproat dihydrate, retigabine, talinolol, fosinopril, doxazosin, metoprolol, nifedipine, norfenefrine-HCl, dihydroergotamine mesilate, salbutamol, terbutaline sulfate, theophylline, furosemide, piretanide, buflomedil, naftidrofuryl, pentoxifylline, trinitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine, bezafibrate, fenofibrate, xantinol, sumatriptan, levodopa benserazide mixture, levodopa carbidopa mixture, amitriptyline, venlafaxine-HCl, thioridazine, lithium carbonate, lithium acetate, and pharmaceutically acceptable salts thereof; and b.) a single release-controlling agent consisting of one or more sucrose esters of fatty acids.
2. The oral pharmaceutical formulation of claim 1, wherein the release rate is a sustained or delayed release.
3. The oral pharmaceutical formulation of claim 1, wherein said formulation is a single unit, or a multiple unit dosage form.
4. The oral pharmaceutical formulation of claim 1, having a dosage form of granules, pellets, tablets, film tablets, microtablets, sugar coated tablets, capsules, or special therapeutic dosage forms.
5. The oral pharmaceutical formulation of claim 1, wherein said active ingredient is embedded in a matrix of said sucrose ester of fatty acid.
6. The oral pharmaceutical formulation of claim 1, wherein said sucrose ester of a fatty acid is a mono-, di-, tri- or polyesters of sucrose with a saturated and/or unsaturated fatty acid of medium to long chain length.
7. The oral pharmaceutical formulation of claim 6, wherein said fatty acid is a C12 to C22 fatty acid.
8. The oral pharmaceutical formulation of claim 7, wherein said fatty acid is one or more of stearic acid, palmitic acid, leuric acid, behemic acid, and oleic acid.
9. The oral pharmaceutical formulation of claim 1, wherein said sucrose ester has an HLB
value of from about 1 to about 16.
value of from about 1 to about 16.
10. The oral pharmaceutical formulation of claim 1, wherein said sucrose ester has a melting point of from about 30°C to about 200°C.
11. The oral pharmaceutical formulation of claim 10, wherein said melting point is from about 40°C to about 150°C.
12. The oral pharmaceutical formulation of claim 1, having a dosage form of a granulate, said granulate containing from about 1 to about 95% wt. of said sucrose ester.
13. The oral pharmaceutical formulation of claim 1, wherein the concentration of said sucrose ester is from about 5 to about 50% wt.
14. An oral pharmaceutical formulation having a dosage form of granules or pellets with variably adjustable release rates, which comprises one or more active ingredients, and one or more sucrose ester of a fatty acid as the sole release-controlling agent for said active ingredient, wherein said granules or pellets are coated with said sucrose ester of a fatty acid.
15. The oral pharmaceutical formulation of claim 14, wherein the concentration of said sucrose ester in said coating is from about 1% to about 60% wt. based on the coated formulation.
16. The oral pharmaceutical formulation of claim 15, wherein the concentration of said sucrose ester in said coating is from about 3% to about 20% wt. based on the coated formulation.
17. The oral pharmaceutical formulation of claim 14, wherein said sucrose ester of a fatty acid is a mono-, di-, tri- or polyesters of sucrose with a saturated and/or unsaturated fatty acid of medium to long chain length.
18. The oral pharmaceutical formulation of claim 14, wherein said fatty acid is a C12 to C22 fatty acid.
19. The oral pharmaceutical formulation of claim 14, wherein said fatty acid is one or more of stearic acid, palmitic acid, leuric acid, behemic acid, and oleic acid.
20. The oral pharmaceutical formulation of claim 14, wherein said active ingredient is one or more of an analeptic agent, antihypoxemic agent, analgesic, antirheumatic agent, antiallergic agent, antiarrhythmic agent, antidementia agent, antidiabetic agent, antiemetic agent, antivertiginous agent, antiepileptic agent, antihypertensive agent, anti-hypotensive agent, broncholytic agent, antiasthmatic agent, diuretic, circulation-promoter, hypnotic agent, sedative, cardiac agent, lipid-lowering agent, antimigraine preparation, muscle relaxants, agents against extrapyramidal disorders, antiParkinson agent, and psycho-pharmaceuticals.
21. The oral pharmaceutic formulation of claim 14 which contains as active ingredient one or more of caffeine, diclofenac, morphine, tramadol, tilidine, nicargoline, pentifylline, vincamine, flupirtine, azelastine, pseudoephedrine, calcium valproate, quinidine, disopyramide, diltiazem, verapamil, piracetam, nicergolin, xantino nicotinate, pentifyllin, vincamin, glibenclamide, betahistin dimesilate, dimenhydrinate, carbamazepine, valproic acid, calcium valproat dihydrate, retigabine, talinolol, fosinopril, doxazosin, metoprolol, nifedipine, norfenefrine-HCl, dihydroergotamine mesilate, salbutamol, terbutaline sulfate, theophylline, furosemide, piretanide, buflomedil, naftidrofuryl, pentoxifylline, trinitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine, bezafibrate, fenofibrate, xantinol, sumatriptan, levodopa benserazide mixture, levodopa carbidopa mixture, amitriptyline, venlafaxine-HCl, thioridazine, lithium carbonate, lithium acetate, or pharmaceutically acceptable salts thereof.
22. A method for preparing the oral pharmaceutical formulation of claim 1, wherein the dosage form is a granule or a pellet, which comprises melting the oral formulation, and granulating or pelletizing the melt.
23. The method of claim 22, said melting comprising heating said formulation with stirring or in a fluidized bed to a temperature at which said sucrose ester softens, commences to melt at the surface, or completely melts, forming said granules or pellets, and cooling them.
24. The method of claim 23, which comprises heating said active ingredient in powder form, and adding said sucrose ester to the heated powder.
25. The method of claim 23, wherein said heating is carried out in a high speed mixer, a high shear mixer, fluidized bed, or a rotor granulator.
26. The method of claim 22, wherein said formulation further comprises a plasticiser.
27. The method of claim 23, wherein said formulation further comprises a plasticiser.
28. The method of claim 26, wherein said plasticiser is one or more of triethyl citrate, acetyl triethyl citrate, triacetin and dibutyl sebacate.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10010509.2 | 2000-03-08 | ||
DE2000110509 DE10010509A1 (en) | 2000-03-08 | 2000-03-08 | Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
US18796200P | 2000-03-09 | 2000-03-09 | |
US60/187,992 | 2000-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2339913A1 CA2339913A1 (en) | 2001-09-08 |
CA2339913C true CA2339913C (en) | 2009-02-24 |
Family
ID=26004678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002339913A Expired - Fee Related CA2339913C (en) | 2000-03-08 | 2001-03-07 | Pharmaceutical formulations and method for making |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP1267828B1 (en) |
JP (1) | JP2003528829A (en) |
KR (1) | KR20020083171A (en) |
CN (1) | CN1212831C (en) |
AT (1) | ATE334659T1 (en) |
AU (1) | AU2001250365A1 (en) |
BG (1) | BG107064A (en) |
BR (1) | BR0109036A (en) |
CA (1) | CA2339913C (en) |
CZ (1) | CZ20023009A3 (en) |
DE (1) | DE50110617D1 (en) |
EA (1) | EA200200951A1 (en) |
EE (1) | EE200200504A (en) |
GE (1) | GEP20053455B (en) |
HK (1) | HK1054697A1 (en) |
HR (1) | HRP20020804B1 (en) |
HU (1) | HUP0204513A3 (en) |
IS (1) | IS6511A (en) |
NO (1) | NO20024237L (en) |
NZ (1) | NZ521215A (en) |
PL (1) | PL202935B1 (en) |
SK (1) | SK13252002A3 (en) |
WO (1) | WO2001066081A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1490031A1 (en) * | 2002-03-07 | 2004-12-29 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
CA2509259A1 (en) * | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
DE10341264A1 (en) * | 2003-09-04 | 2005-03-24 | Grünenthal GmbH | Melt-formulated, multiparticulate oral dosage form |
JP2007533733A (en) * | 2004-04-22 | 2007-11-22 | モル リサーチ アプリケーションズ リミテッド | How to control food intake |
AU2009270768A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
DE102009013613A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Dry processing of retigabine |
DE102009013612A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Retigabine tablets, preferably with modified release |
DE102009013611A1 (en) | 2009-03-17 | 2010-09-23 | Ratiopharm Gmbh | Solid retigabine in non-crystalline form |
BR112012018173A2 (en) * | 2010-01-20 | 2017-08-29 | Valeant Pharmaceuticals Int | "MODIFIED RELEASE FORMULATION AND METHOD OF USE" |
EP2729176A1 (en) | 2011-07-05 | 2014-05-14 | Contera Pharma APS | The use of serotonin receptor agonists for treatment of movement disorders |
US9616025B2 (en) * | 2013-10-29 | 2017-04-11 | Echo Pharmaceuticals B.V. | Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
US11331268B2 (en) * | 2016-11-18 | 2022-05-17 | The University Of Western Australia | Taste masking product |
CN107441055A (en) * | 2017-08-03 | 2017-12-08 | 山东则正医药技术有限公司 | A kind of preparation method of controlled release drug |
CN108853044B (en) * | 2018-07-06 | 2020-11-06 | 郑州明泽医药科技有限公司 | Nifedipine sustained release tablet and preparation method thereof |
CN109679147B (en) * | 2018-12-28 | 2021-05-11 | 广西科技师范学院 | Plant microfine fiber sucrose fatty acid ester enrichment and preparation method thereof |
GB201904767D0 (en) | 2019-04-04 | 2019-05-22 | Orexo Ab | New pharmaceutical compositions |
WO2021145625A1 (en) * | 2020-01-13 | 2021-07-22 | 한국유나이티드제약 주식회사 | Pharmaceutical composition comprising r-thioctic acid or pharmaceutically acceptable salt thereof and enteric coating base material |
CN111513192A (en) * | 2020-05-19 | 2020-08-11 | 北京中联华康科技有限公司 | Esterified cysteamine hydrochloride stable powder and preparation method and application thereof |
CN114983964B (en) * | 2022-06-24 | 2024-05-03 | 广东恒健制药有限公司 | Cefdinir granule and preparation method thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63101320A (en) * | 1986-10-17 | 1988-05-06 | Dainippon Pharmaceut Co Ltd | Calcium valproate preparation |
JPH07267850A (en) * | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | Medicine composition prevented in unpleasant taste and method for producing the same |
JP4078567B2 (en) * | 1997-04-25 | 2008-04-23 | 東和薬品株式会社 | Sustained release microcapsules and production method thereof |
JP4299384B2 (en) * | 1997-07-15 | 2009-07-22 | 富山化学工業株式会社 | Anti-elution delay fine granules |
HU230889B1 (en) * | 1998-03-26 | 2018-12-28 | Astellas Pharma Inc. | Sustained release preparations |
DE19840152A1 (en) * | 1998-09-03 | 2000-03-09 | Dresden Arzneimittel | Pharmaceutical compositions containing calcium valproate with a delayed release of active substance, process for their preparation and their use |
DE19916383A1 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition with an extrusion |
-
2001
- 2001-03-06 CN CNB018061893A patent/CN1212831C/en not_active Expired - Fee Related
- 2001-03-06 NZ NZ521215A patent/NZ521215A/en unknown
- 2001-03-06 DE DE50110617T patent/DE50110617D1/en not_active Revoked
- 2001-03-06 PL PL362547A patent/PL202935B1/en not_active IP Right Cessation
- 2001-03-06 JP JP2001564734A patent/JP2003528829A/en active Pending
- 2001-03-06 EA EA200200951A patent/EA200200951A1/en unknown
- 2001-03-06 BR BR0109036-4A patent/BR0109036A/en not_active Application Discontinuation
- 2001-03-06 HU HU0204513A patent/HUP0204513A3/en unknown
- 2001-03-06 CZ CZ20023009A patent/CZ20023009A3/en unknown
- 2001-03-06 EE EEP200200504A patent/EE200200504A/en unknown
- 2001-03-06 AT AT01923641T patent/ATE334659T1/en not_active IP Right Cessation
- 2001-03-06 SK SK1325-2002A patent/SK13252002A3/en not_active Application Discontinuation
- 2001-03-06 WO PCT/EP2001/002500 patent/WO2001066081A2/en active IP Right Grant
- 2001-03-06 AU AU2001250365A patent/AU2001250365A1/en not_active Abandoned
- 2001-03-06 KR KR1020027011672A patent/KR20020083171A/en not_active Application Discontinuation
- 2001-03-06 EP EP01923641A patent/EP1267828B1/en not_active Revoked
- 2001-03-06 GE GE4946A patent/GEP20053455B/en unknown
- 2001-03-07 CA CA002339913A patent/CA2339913C/en not_active Expired - Fee Related
-
2002
- 2002-08-20 IS IS6511A patent/IS6511A/en unknown
- 2002-09-05 BG BG107064A patent/BG107064A/en unknown
- 2002-09-05 NO NO20024237A patent/NO20024237L/en not_active Application Discontinuation
- 2002-10-07 HR HR20020804A patent/HRP20020804B1/en not_active IP Right Cessation
-
2003
- 2003-09-30 HK HK03107084A patent/HK1054697A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2001066081A2 (en) | 2001-09-13 |
WO2001066081A3 (en) | 2002-03-14 |
NO20024237D0 (en) | 2002-09-05 |
PL362547A1 (en) | 2004-11-02 |
AU2001250365A1 (en) | 2001-09-17 |
HRP20020804B1 (en) | 2008-06-30 |
HRP20020804A2 (en) | 2004-12-31 |
HUP0204513A2 (en) | 2003-05-28 |
HK1054697A1 (en) | 2003-12-12 |
EP1267828B1 (en) | 2006-08-02 |
NZ521215A (en) | 2005-04-29 |
SK13252002A3 (en) | 2003-07-01 |
EE200200504A (en) | 2004-02-16 |
NO20024237L (en) | 2002-09-05 |
PL202935B1 (en) | 2009-08-31 |
EP1267828A2 (en) | 2003-01-02 |
EA200200951A1 (en) | 2003-02-27 |
GEP20053455B (en) | 2005-02-25 |
CZ20023009A3 (en) | 2003-06-18 |
CN1418091A (en) | 2003-05-14 |
CN1212831C (en) | 2005-08-03 |
IS6511A (en) | 2002-08-20 |
KR20020083171A (en) | 2002-11-01 |
BR0109036A (en) | 2003-03-18 |
ATE334659T1 (en) | 2006-08-15 |
BG107064A (en) | 2003-04-30 |
JP2003528829A (en) | 2003-09-30 |
HUP0204513A3 (en) | 2004-06-28 |
CA2339913A1 (en) | 2001-09-08 |
DE50110617D1 (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020015730A1 (en) | Pharmaceutical formulations and method for making | |
CA2339913C (en) | Pharmaceutical formulations and method for making | |
US5807583A (en) | Process for the preparation of sustained release pellets | |
EP0785775B2 (en) | Melt-extruded orally administrable opioid formulations | |
JP4149527B2 (en) | Liquiflash particles and method for producing the same | |
KR100365572B1 (en) | Sustained-release and pharmaceutical compositions | |
KR0148002B1 (en) | Sustained release preparation | |
JP2003528829A6 (en) | Pharmaceutical preparations | |
JPH04217913A (en) | Coated pharmaceutical and its production | |
EP2136792B1 (en) | Hot-melt micropellets | |
BG106839A (en) | Therapeutic agents | |
CA2449352C (en) | Nsaid formulation comprising a granular composition and an extra-granular composition | |
AU2002302786A1 (en) | Nsaid formulation comprising a granular composition and an extra-granular composition | |
JPH0530810B2 (en) | ||
EP2376061A1 (en) | Aqueous coacervate composition comprising poorly water-soluble biologically-active agents | |
ZA200207050B (en) | Pharmaceutical preparations. | |
BG62316B1 (en) | Pharmaceutical forms with continuous release and method for their preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |